(Q37965612)

26 August 2017

title

A review of gliptins in 2011. (English)

1 reference

26 August 2017

André J Scheen

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

81-99

1 reference

New drugs for type 2 diabetes mellitus: what is their place in therapy?

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Vildagliptin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Vildagliptin in clinical practice: a review of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Linagliptin: in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

DPP-4 inhibitors: what may be the clinical differentiators?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Regulation of glucagon secretion by incretins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Current management strategies for coexisting diabetes mellitus and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Clinical approaches to preserve beta-cell function in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Sitagliptin-associated drug allergy: review of spontaneous adverse event reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Addition of incretin therapy to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Drug evaluation: vildagliptin-metformin single-tablet combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

GLP-1 agonists and dipeptidyl-peptidase IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Incretin-based therapies in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642866

10.1517/14656566.2012.642866

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference